Medicare Enrolled
Dr. Elizabeth Gunderson, MD
Medical Oncology · Spokane Valley, WA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Gunderson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gunderson?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gunderson
Dr. Elizabeth Gunderson is a medical oncology specialist in Spokane Valley, WA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Gunderson performed 122,005 Medicare services across 2,003 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gunderson received a total of $553 from 16 pharmaceutical and/or device companies across 28 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gunderson is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in WA
$553 industry payments
Medicare Practice Summary
Medicare Utilization ↗122,005
Medicare services
Top 3% in WA for medical oncology
2,003
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,421 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 25,420 | $24 | $71 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
18,750 | $1 | $4 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
13,760 | $0 | $12 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
12,600 | $2 | $24 |
| Denosumab injection (Prolia/Xgeva) | 12,240 | $18 | $52 |
| Pembrolizumab injection (Keytruda) | 11,801 | $43 | $132 |
| Anti-nausea injection (aprepitant) | 8,060 | $1 | $8 |
| Paclitaxel chemotherapy injection | 5,035 | $0 | $8 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,324 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,560 | $0 | $11 |
| Injection, fulvestrant, 25 mg | 1,560 | $8 | $244 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,110 | $1 | $114 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
635 | $12 | $74 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
613 | $8 | $12 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
610 | $135 | $359 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
602 | $8 | $40 |
| Injection, leucovorin calcium, per 50 mg | 602 | $3 | $10 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
559 | $2 | $8 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
472 | $105 | $472 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
395 | $11 | $71 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
310 | $2 | $345 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
188 | $22 | $105 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
180 | $0 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
175 | $52 | $232 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
157 | $27 | $120 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
154 | $6 | $135 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
118 | $50 | $225 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
112 | $18 | $88 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
106 | $94 | $266 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
100 | $10 | $53 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
83 | $1 | $10 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
70 | $2 | $34 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
66 | $26 | $176 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 59 | $133 | $3,677 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
58 | $16 | $69 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
57 | $1 | $18 |
| Refilling and maintenance of portable pump This service involves refilling and performing maintenance on a portable pump. |
54 | $102 | $462 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
41 | $45 | $199 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
41 | $93 | $269 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
38 | $3 | $12 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
38 | $1 | $23 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
26 | $30 | $169 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
25 | $63 | $169 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
23 | $59 | $177 |
| New patient office visit, complex (60-74 min) | 18 | $155 | $513 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
16.2% high complexity
81.7% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$553
Total received (2021-2024)
Avg $138/year across 4 years
Bottom 32% in WA for medical oncology
16
Companies
28
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$541 (97.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (2.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$447
2023
$79
2022
$15
2021
$12
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$72
Novartis Pharmaceuticals Corporation
$64
Lilly USA, LLC
$48
Incyte Corporation
$35
Acrotech Biopharma Inc.
$28
E.R. Squibb & Sons, L.L.C.
$26
Myriad Genetic Laboratories, Inc.
$24
Janssen Biotech, Inc.
$20
Mirati Therapeutics, Inc.
$20
Fennec Pharmaceuticals, Inc.
$20
Dendreon Pharmaceuticals LLC
$20
ADC Therapeutics America, Inc.
$19
Blueprint Medicines Corporation
$18
Gilead Sciences, Inc.
$18
Exelixis Inc.
$14
Top 3 companies account for 41.1% of 2024 payments
All-time payments by company (2021-2024) ›
AstraZeneca Pharmaceuticals LP
$72
Novartis Pharmaceuticals Corporation
$64
Myriad Genetic Laboratories, Inc.
$48
Lilly USA, LLC
$48
Janssen Biotech, Inc.
$44
Dendreon Pharmaceuticals LLC
$36
Incyte Corporation
$35
Celgene Corporation
$30
Gilead Sciences, Inc.
$30
Acrotech Biopharma Inc.
$28
E.R. Squibb & Sons, L.L.C.
$26
Mirati Therapeutics, Inc.
$20
Fennec Pharmaceuticals, Inc.
$20
ADC Therapeutics America, Inc.
$19
Blueprint Medicines Corporation
$18
Exelixis Inc.
$14
Top 3 companies account for 33.3% of all-time payments
Associated products mentioned in payments ›
AYVAKIT · BELEODAQ · CABOMETYX · DARZALEX · ENHERTU · IMFINZI · JAKAFI · KISQALI · KRAZATI · MYRISK · OPDIVO · PEMAZYRE · PRECISETUMOR · PROVENGE · Pedmark · REBLOZYL · SCEMBLIX · VERZENIO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
10
Per 100K population
1.8
County median income
$73,513
Nearest hospital
MULTICARE VALLEY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Gunderson is a mixed practice specialist, with above-average Medicare volume (top 3% in WA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Gunderson experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Gunderson performed 25,420 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gunderson receive payments from pharmaceutical companies?
Yes. Dr. Gunderson received a total of $553 from 16 companies across 28 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gunderson's costs compare to other medical oncologists in Spokane Valley?
Dr. Gunderson's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gunderson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Spokane Valley
Browse medical oncologists in Spokane Valley ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in WA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in WA
Which WA medical oncologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology